Professor Eivind Hovig, head of the genotyping core facility, and head of the bioinformatics core facility, stated, "We have come to recognize that the antibody array products provided by RayBiotech provide excellent possibilities for biomarker screening, and we see that the quality and breadth of the products are valuable additions to ongoing research at our institutions. We are currently undertaking large studies involving several groups across a number of research disciplines based on RayBiotech array products. We are very happy with this partnership, as we foresee increased usage of these very useful products in the near future."
About RayBiotech, Inc.
RayBiotech (www.raybiotech.com) pioneered the development of antibody and protein array technologies and provides reliable high-throughput platforms for identifying disease mechanisms, screening and validation of novel biomarkers and identification of new drug targets. In 2001, RayBiotech introduced the first commercially available cytokine antibody array. Since then, RayBiotech array products have been featured in hundreds of publications, including some in top-tier journals: Nature, Nature Medicine, Cell, Lancet, PNAS (USA), and many others. Offering more antibody array choices than any of its competitors, RayBiotech has established a leading reputation for the high quality and innovative developments provided to the research community. RayBiotech continues to lead in the development of protein array technologies and is focused on further meeting the needs of clients in translating new knowledge of human biology to improved health. A spin-off from Emory University's School of Medicine, RayBiotech is privately owned, with headquarters in metropolitan Atlanta (Norcross, GA).
About the Institute for Cancer Research at Oslo
|SOURCE RayBiotech, Inc.|
Copyright©2012 PR Newswire.
All rights reserved